“This is a very unique study for a set of patients who have really run out of options,” said Daniel Monti, M.D., director of the Myrna Brind Center of Integrative Medicine, and primary investigator of the study. “Vitamin C administered intravenously has shown great promise in the laboratory and there has been some anecdotal data in cancer patients, but no one has really ever run a detailed study on humans. Vitamin C doesn’t cost much and is very low in toxicity, making it a particularly desirable agent for further study.”
Recent research conducted by the NIH collaborators of this study has shown that when given in sufficient amounts intravenously, vitamin C converts to hydrogen peroxide. When applied to certain non-Hodgkin lymphoma cells in the laboratory, the converted hydrogen peroxide kills them while leaving the surrounding healthy cells intact.
“Previous human studies have been flawed because the vitamin C was given orally versus intravenously,” said Monti. “The problem with that is the oral route tightly limits the amount of vitamin C that can get into the bloodstream. When vitamin C is given intravenously you can get up to 70 times more of the vitamin into the blood versus the same dose given orally. It is these high blood levels that are required to get the mechanism of action, vitamin C converting to hydrogen peroxide around the cancer cells, to occur. Although other cancers could be a contender for this intervention, the preliminary data on non-Hodgkin lymphoma cells is why we decided to start with this disease.”
The study will begin with 20 non-Hodgkin lymphoma patients who have failed standard therapy. Each study participant will be given varied intravenous doses of vitamin C three times a week. The patients will be evaluated and monitored for progression of their disease. The study’s goals are to show diminished progression of the disease in participating patients.
“As leaders in the field of integrative medicine, Jefferson is always seeking new and innovative therapies for our patients,” concluded Monti. “We want to look in every corner for solutions. This study is a unique collaboration of several clinical and research specialists. If this study yields positive data we will do further studies to expand the availability of this intriguing therapy.”
Source: Thomas Jefferson University
Related stories:
Clinical study to examine role of vitamin D in kidney disease
Vitamin D is the key to preventing rickets and osteoporosis, but Rockefeller University scientists suspect it may also play a role in heading off atherosclerosis in people with chronic kidney disease.
For coronary artery disease patients, B vitamins may not reduce cardiovascular events
In a large clinical trial involving patients with coronary artery disease, use of B vitamins was not effective for preventing death or cardiovascular events, according to a study published in the August 20 issue of
JAMA.
Hormone level may reflect mortality risk among dialysis patients
A new study suggests that monitoring levels of a hormone called fibroblast growth factor 23 (FGF-23) may provide information crucial to the treatment of patients with kidney failure. In the Aug. 7
New England Journal of Medicine, researchers from Massachusetts General Hospital (MGH) report that patients with elevated levels of FGF-23 when beginning hemodialysis had a significantly increased risk of death within the first year of treatment, regardless of whether they had other risk factors. The study also found evidence that FGF-23 levels may differ between racial groups, which may relate to observed disparities in survival of dialysis patients.
Vitamin C injections slow tumor growth in mice
High-dose injections of vitamin C, also known as ascorbate or ascorbic acid, reduced tumor weight and growth rate by about 50 percent in mouse models of brain, ovarian, and pancreatic cancers, researchers from the National Institutes of Health (NIH) report in the August 5, 2008, issue of the
Proceedings of the National Academy of Sciences. The researchers traced ascorbate's anti-cancer effect to the formation of hydrogen peroxide in the extracellular fluid surrounding the tumors. Normal cells were unaffected.
Researchers unravel key mechanism of cellular damage in aging and disease
Researchers have taken a first snapshot of how a class of highly reactive molecules inflicts cellular damage as part of aging, heart disease, stroke, cancer, diabetes, kidney disease and Alzheimer's disease to name a few. According to a study published today in the journal
Cell, researchers have discovered a tool that can monitor related damage and determine the degree to which antioxidant drugs effectively combat disease.
Drug lowers body's 'set point' to control hyperparathyroidism in dialysis patients
A medication called cinacalcet—an important part of treatment to control high levels of parathyroid hormone (PTH) in patients receiving dialysis for end-stage renal disease (ESRD)—works by resetting the balance between calcium and PTH levels, according to a study in the November
Journal of the American Society of Nephrology (JASN).
Complementary medicines can help mild depression and premenstrual syndrome
Complementary medicines can help mild depression and premenstrual syndrome. Not all dietary supplements and "alternative" products are harmless though. German Institute urges consumers to be more critical of health claims.
New blood clot guidelines for pregnant women
Blood clot recommendations highlight challenges for pediatric and pre-surgery populations
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies. Published as a supplement in the June issue of
CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and Thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more than 700 of the most comprehensive recommendations related to the prevention, treatment, and long-term management of thrombotic disorders. The guidelines include chapters on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing peri- and postoperative patients, while also reinforcing previous guidelines related to the routine use of preventive therapies, including aspirin.